PROX1

IDENTIFYING INHIBITORS OF PROX1 IN COLORECTAL CANCER

Coordinatore	HELSINGIN YLIOPISTO    more  Organization address address: YLIOPISTONKATU 4 city: HELSINGIN YLIOPISTO postcode: 14 contact info Titolo: Ms. Nome: Katariina Cognome: Vainio-Mattila Email: send email Telefono: +358 50 415 0146 Fax: +358 9 191 25044
Nazionalità Coordinatore	Finland [FI]
Totale costo	0 €
EC contributo	184˙759 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-03-01   -   2011-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	HELSINGIN YLIOPISTO  Organization address address: YLIOPISTONKATU 4 city: HELSINGIN YLIOPISTO postcode: 14 contact info Titolo: Ms. Nome: Katariina Cognome: Vainio-Mattila Email: send email Telefono: +358 50 415 0146 Fax: +358 9 191 25044	FI (HELSINGIN YLIOPISTO)	coordinator	184˙759.19

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Colorectal cancer (CRC) is one of the leading causes of cancer related mortality in the developed countries. Interestingly, the host laboratory has recently discovered that the homeobox transcription factor PROX1 is overexpressed in the vast majority of human CRCs as well as in mouse models of intestinal cancer with abnormal beta-catenin/TCF signaling. Furthermore, they provided evidence that PROX1 is regulated by the high concentration of beta-catenin and this regulation seems to be tissue specific. As PROX1 expression was found to be specifically associated with the transition from benign to malignant tumor phenotype and in normal colonic and small intestinal epithelium PROX1 expression is restricted only to some enteroendocrine cells, targeting PROX1 seems to be a novel possibility for anti-CRC drugs. The aim of this proposal is to develop an endodermal cell model for the analysis of PROX1 function in the intestine by using induced pluripotent stem cells, furthermore, to identify inhibitors that regulate PROX1 activity or kill PROX1 cells in CRC and to validate their effect. To achieve the aims, dominant negative constructs will be generated, the direct target genes of PROX1 will be determined by combining expression and ChIP-on-Chip microarray data, high-throughput chemical library screening will be carried out and the effect of candidates will be validated by using different in vitro and in vivo systems.'